CBio Secures Another Clinical Trial Milestone
Mar 12th, 2010 | By buddy1 | Category: Health & Wellness News, Pain ManagementAustralian drug development company CBio Limited (ASX: CBZ) announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA)…
